Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR). Indirect T-cell therapy leverages the capability of tumor-targeted bispecific antibodies to redirect T-cells to the tumor. This report package includes two full reports covering both aspects of T-cell immunotherapy of cancer.

The original reports were published in May and August 2016, respectively:

• T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals
  

• TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page.